Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-HERCULES: Long-term Caplacizumab in aTTP
NCT02878603Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2016
- Primary completion
- Oct 2020
- Modality
- Nanobodies (VHH)
- Countries
- 13
01
Overview
A Phase 3 trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Started Oct 2016; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT02878603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878603.